Investors

What do doctors say about the Biostage Esophageal Implant?

Biostage has a “breakthrough” technology that is “revolutionary” and would “have considerable clinical use” - all quotes by top surgeons, from Massachusetts General Hospital, Mayo Clinic and Connecticut Children’s Medical Center.

 

 

Stock Information
OTCQBBSTG
Press Releases
Mar 1, 2023
Biostage Announces Chairman and CEO Transition

Existing Board member Jerry He to replace David Green as Chairman and Chief Executive Officer; David Green to remain on the Board and support transition HOLLISTON, Mass., March 1, 2023 /PRNewswire/ --

Jan 12, 2023
Biostage Amends CEO Employment Agreement

Biostage removes Interim qualification from Mr. Green's title, making him Chief Executive Officer. HOLLISTON, Mass., Jan. 12, 2023 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the...

Dec 28, 2022
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer

IQVIA was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials. HOLLISTON, Mass., Dec. 28, 2022 /PRNewswire/ -- Biostage, Inc....

More >

Contact Us

Biostage, Inc.
84 October Hill Road
Suite 11
Holliston, Massachusetts 01746
United States

Phone: 774-233-7300
Toll Free: 855-209-3104
Fax: 774-233-7302

Investor Presentation

  
Download PDF

Fact Sheet